1 to 7 of 7
Sort by

Library Entry
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

Loss-of-function alterations in DNA damage repair (DDR) genes are associated with human tumorigenesis and may determine benefit from immune-oncology (I/O) agents as shown in colon cancer. However, biologic significance and relevance to I/O in metastatic clear cell RCC (ccRCC) are unknown. The...

Library Entry
Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer

Increasing evidence has demonstrated the functional relevance of long non-coding RNAs (lncRNAs) to immunity regulation and the tumor microenvironment in non-small cell lung cancer (NSCLC). However, tumor immune infiltration-associated lncRNAs and their value in improving clinical outcomes and...

Library Entry
Mechanisms regulating PD-L1 expression on tumor and immune cells

The PD-1/PD-L1 checkpoint is a central mediator of immunosuppression in the tumor immune microenvironment (TME) and is primarily associated with IFN-g signaling. To characterize other factors regulating PD-L1 expression on tumor and/or immune cells, the authors investigated TME-resident...

Library Entry
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

In melanoma, there is no companion diagnostic test to predict response to programmed cell death 1 (PD-1) axis immune checkpoint inhibitor (ICI) therapy. In the adjuvant setting, only one in five patients may benefit from ICI, so a biomarker is needed to select those that may or may not benefit....

Library Entry
miR-34a as hub of T cell regulation networks

Micro(mi)RNAs are increasingly recognized as central regulators of immune cell function. While it has been predicted that miRNAs have multiple targets, the majority of these predictions still await experimental confirmation. In this article the authors analyze miR-34a, a well-known tumor...

Library Entry
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges

Tumor mutational burden (TMB), the total number of somatic coding mutations in a tumor, is emerging as a promising biomarker for immunotherapy response in cancer patients. In this review, the authors inventory the collection of available gene panels, illustrating their technical specifications...

Web Page
Journal for ImmunoTherapy of Cancer

The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer. This open access, peer-reviewed journal publishes original research articles, literature reviews, position papers and more on all aspects of tumor immunology and cancer...